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ardiovascular diseases (CVDs), including coronary heart
isease (CHD) as the largest contributor, represent the
ajor cause of death worldwide and will continue to
ncrease in the future, owing to aging of the population, the
pidemic of obesity and the metabolic syndrome including
ype 2 diabetes mellitus, and the rapid transition of devel-
ping countries into industrialized nations and their acqui-
ition of cardiovascular risk factors. Such a perspective will
ecome reality despite an enormous advancement in our
nderstanding of the pathophysiology of atherothrombosis,
dentification of treatable risk factors, and the development
f an armamentarium of potent drugs to combat this wide-
pread disease, including statins, angiotensin-converting
See page 1632
nzyme (ACE) inhibitors/angiotensin receptor blockers, and
ntiplatelet drugs. Nevertheless, between 1980 and 2000, a
emarkable reduction of CHD deaths primarily in the
lderly has been observed in several countries, including the
.S., where deaths were reduced by approximately 50% (1).
bout 40% of the total reduction in CHD deaths has been
ttributed to various therapeutic strategies like aggressive
reatment in secondary prevention after myocardial infarc-
ion (MI), initial revascularization for acute MI, and treat-
ent of heart failure, and more than 50% was related to
eduction in risk factors (of which reduction in cholesterol
nd blood pressure accounted for 24% and 20%, respec-
ively, and another 20% by reduction in smoking and
ncrease in physical activity). However, these positive trends
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Internal Medicine II–Cardiology, University of Ulm
edical Center, Ulm, Germany. The author has received honoraria for lectures froma
laxoSmithKline, the manufacturer of darapladib, and has been a member of an
dvisory board to GlaxoSmithKline.ight level off soon, in particular in younger age groups,
wing to the counteracting developments just described.
Statins have been proven most efficacious in numerous
andomized controlled clinical trials, resulting in a profound
eduction of relative risk (RRR) for a first MI or a recurrent
I between 19% and 38% (2). A recent meta-analysis
nvestigating the effects of 2 ACE inhibitors, ramipril and
erindopril, found a 27% RRR in the group already aggres-
ively pre-treated with revascularization, anti-platelets,
ipid-lowering drugs, and beta-blockers (3). Similar results
ave been obtained for aspirin and thienopyridines like
lopidogrel. However, in diabetic patients, even intensive
reatment including lifestyle changes and control of
lucose, blood pressure, and lipids was still associated
ith a 19% CVD event rate over 5 years compared with
ven 32% in the conventionally treated group (4). Un-
ortunately, the individual risk reductions achieved by
ach drug group do not add up, leaving us with an RRR
f 30% to 40% at best, even in populations receiving
ggressive polypharmacy. Conversely, this means that
0% to 70% of patients do experience an event despite the
est available medical treatment.
Such data clearly raise the question: how to improve the
urrent situation? One point certainly relates to an improve-
ent in the control of risk factors through lifestyle changes
nd the achievement of better compliance of patients in
rimary prevention in whom drug therapy is indicated. An
lternative strategy might consist in the development of new
rugs that would be complementary to the presently avail-
ble compounds. Because modification of the lipid profile
as been proven to be the most effective intervention to
educe CHD events, great efforts are being undertaken by
he pharmaceutical industry to develop new candidates in
his area or to improve pharmacokinetics and side effects of
lder compounds, such as drugs to further modify low-
ensity lipoprotein cholesterol (LDL-C) or high-density
ipoprotein cholesterol (HDL-C). In addition, basic and
linical research have convincingly demonstrated that ath-
rosclerosis carries several typical features of a local and
ystemic inflammatory process (5). Thus, intervening with
arious modulators of plaque biology that are directly
nvolved in inflammatory and destabilizing processes in the
laque might also be promising. Lipoprotein-associated
hospholipase A2 (Lp-PLA2) might be such a candidate
hat could represent a link between lipid metabolism and the
nflammatory response.
Lipoprotein-associated phospholipase A2, a 45.4 kDa
rotein, is a calcium-independent member of the phospho-
ipase A2 family (reviewed in [6]) that is mainly produced by
onocytes, macrophages, T-lymphocytes, and mast cells. In
he bloodstream, two-thirds of the Lp-PLA2 circulates
rimarily bound to LDL-C; the other one-third is distrib-
ted between HDL-C and very-low-density lipoproteins.
urthermore, Lp-PLA2 has been detected in both rabbit
nd human atherosclerotic lesions. Moreover, in investigat-
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April 29, 2008:1642–4 Editorial Commentng Lp-PLA2 expression in coronary segments from sudden
oronary death patients, a strong expression of this enzyme
ithin the fibrous cap of coronary lesions prone to rupture
as found, whereas in less advanced lesions, Lp-PLA2
xpression was relatively low or even absent. The Lp-PLA2
ight act pro-atherogenic by its ability to promote oxida-
ion of LDL-C. After LDL oxidation within the arterial
all, Lp-PLA2 cleaves an oxidized phosphatidylcholine
omponent of the lipoprotein particle, generating 2 potent
ro-inflammatory and pro-atherogenic mediators, namely
ysophosphatidylcholine (LysoPC) and oxidized fatty acid.
ro-inflammatory actions of LysoPC as well as those of
xidized fatty acid trigger a cascade of events that might
irectly promote atherogenesis. The LysoPC is a potent
hemoattractant for T-cells and monocytes, promotes en-
othelial cell dysfunction, stimulates macrophage prolifera-
ion, and induces apoptosis in smooth muscle cells and
acrophages. Thus, Lp-PLA2 might represent an impor-
ant “missing link” between the oxidative modification of
ow-density lipoprotein in the arterial vascular wall and local
nflammatory processes within the atherosclerotic plaque.
Over the last 7 years, a large body of evidence has been
ccumulated that demonstrates that increased circulating
oncentrations of Lp-PLA2 mass or elevated activity of the
nzyme are positively associated with various cardiovascular
nd points. Such results have been reported in initially
ealthy subjects from representative population-based stud-
es as well as in patients with manifest CHD (6), although
he association was not stronger than that for other emerg-
ng biomarkers, such as C-reactive protein (CRP), but
ather showed an additive value in conjunction with this
olecule. There were some controversial results concerning
he association of Lp-PLA2 with subclinical atherosclerotic
isease, but a recent report (7) demonstrated that Lp-PLA2
as independently associated with coronary artery endothe-
ial dysfunction, an established precursor of manifest ath-
rosclerosis, and was a strong predictor of endothelial
ysfunction in humans. In addition, the same group (8)
howed local production of Lp-PLA2 in early atherosclero-
is and that LysoPC, the active product of Lp-PLA2, was
ssociated with endothelial dysfunction. Thus, evidence on
arious scientific levels argues for a direct involvement of
p-PLA2 in the atherosclerotic process.
The Lp-PLA2 could also represent an attractive novel
herapeutic target, because azetidinones, a new class of
ompounds acting as acylating inhibitors of the enzymatic
ctivity of Lp-PLA2, have shown the ability to interfere
ith the biological (toxic) sequelae of oxidized LDL,
amely chemoattraction of monocytes and apoptosis in
acrophages (6). Decreased accumulation of LysoPC and
xidized fatty acid contents were also seen with this com-
ound. Moreover, experimental studies in Watanabe heri-
able hyperlipidemic rabbits have shown a 95% inhibition of
p-PLA2 in atherosclerotic plaque and a reduction of
therosclerotic lesion formation (6). In addition, oral ad-
inistration of an Lp-PLA2 inhibitor to healthy volunteers Bn a phase I clinical trial demonstrated almost the same
ose-dependent reduction in Lp-PLA2 activity of up to
5%, thereby identifying this compound as a very potent
p-PLA2 inhibitor with a suitable profile for evaluation in
umans (6). Furthermore, results from an early phase II trial
howed that administration of 40 and 80 mg of SB-480848
darapladib) to patients for 14 days before carotid endarter-
ctomy resulted in the inhibition of Lp-PLA2 plasma
ctivity by 52% and 81%, respectively, and the inhibition of
p-PLA2 plaque activity by 52% and 80%, respectively,
ompared with placebo (6).
In this issue of the Journal, Mohler et al. (9) present data
rom a large multicenter, randomized double-blind placebo-
ontrolled trial investigating the effect of darapladib (SB-
80848), a selective Lp-PLA2 inhibitor, on Lp-PLA2
ctivity and a panel of biomarkers reflecting different path-
ays of the pathophysiology of atherosclerosis. The study
opulation comprised of 959 patients with stable CHD or
HD risk equivalents; all were on a polypharmacy regimen
nd treated with 3 different doses of darapladib (40, 80, and
60 mg) over 12 weeks against a background of atorvastatin
0 and 80 mg. Most importantly, no safety concerns were
oted. Darapladib inhibited Lp-PLA2 activity in a dose-
ependent manner in both statin groups at different
DL-C levels but did not affect LDL-C levels. At 12
eeks, darapladib in the highest dose significantly decreased
nterleukin-6 and showed a trend to decreased CRP con-
entrations. There were no effects on myeloperoxidase and
atrix metalloproteinase-9, which might have been owing
o analytic problems, and no alteration of markers of platelet
unction was seen.
What do these data tell us? First, it is reassuring that
o safety issues were reported in almost 1,000 high-risk
atients, although the treatment period was only 3
onths. Thus, we do not know whether there is a
otential for adverse effects long-term. Second, this study
nvestigated blood biomarkers as surrogates of atheroscle-
osis risk, and although the effects were not dramatic and
een only with the highest dose, they point in the right
irection. However, even if there was no signal of harm
n the biomarker profile, it has to be kept in mind that
ecent experience from several trials has painfully dem-
nstrated the limitations of surrogate markers in the
ssessment of drug efficacy. Third, this study does not
rovide information on what is going on inside the vessel
all itself after inhibition of Lp-PLA2 activity. This issue
s presently addressed in the IBIS-2 (Integrated Biomar-
er and Imaging Study) using intravascular ultrasound
rey scale information, virtual histology, and palpography
n 330 patients with stable CHD or acute coronary
yndrome, treated with darapladib for 12 months (9).
In summary, the study by Mohler et al. (10) shows that
arapladib substantially inhibits plasma Lp-PLA2 activ-
ty and suggests a modulation of the systemic inflamma-
ory response in the presence of intensive statin therapy.
ecause inflammation plays a pivotal role in athero-
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Editorial Comment April 29, 2008:1642–4hrombosis and its clinical complications, inhibition of
p-PLA2 might have promise as a suitable strategy to
ombat residual cardiovascular risk in carefully selected
atients.
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